ProCE Banner Activity

Phase I Trial of CD19-Targeted 19-28z CAR T-Cell Therapy in Adult Pts With R/R B-Cell ALL

Slideset Download
Conference Coverage
Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden.

Released: June 12, 2017

Expiration: June 11, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology